Model‐based interspecies interpretation of botulinum neurotoxin type A on muscle‐contraction inhibition

Abstract

AbstractBotulinum neurotoxins (BoNTs) are commonly used in therapeutic and cosmetic applications. One such neurotoxin, BoNT type A (BoNT/A), has been studied widely for its effects on muscle function and contraction. Despite the importance of BoNT/A products, determining the blood concentrations of these toxins can be challenging. To address this, researchers have focused on pharmacodynamic (PD) markers, including compound muscle action potential (CMAP) and digit abduction scoring (DAS). In this study, we aimed to develop a probabilistic kinetic‐pharmacodynamic (K‐PD) model to interpret CMAP and DAS data obtained from mice and rats during the development of BoNT/A products. The researchers also wanted to gain a better understanding of how the estimated parameters from the model relate to the bridging of animal models to human responses. We used female Institute of Cancer Research mice and Sprague‐Dawley (SD) rats to measure CMAP and DAS levels over 32 weeks after administering BoNT/A. We developed a muscle‐contraction inhibition model using a virtual pharmacokinetic (PK) compartment combined with an indirect response model and performed model diagnostics using goodness‐of‐fit analysis, visual predictive checks (VPC), and bootstrap analysis. The CMAP and DAS profiles were dose‐dependent, with recovery times varying depending on the administered dose. The final K‐PD model effectively characterized the data and provided insights into species‐specific differences in the PK and PD parameters. Overall, this study demonstrated the utility of PK‐PD modeling in understanding the effects of BoNT/A and provides a foundation for future research on other BoNT/A products.